Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neurotrope, Inc.NTRP · Entity 144906 | Director | December 01, 2020 | December 03, 2020 |
| Petros Pharmaceuticals, Inc.PTPI · Entity 8730 | Director | June 05, 2026 | June 05, 2026 |
| Q/C TECHNOLOGIES, INC.QCLS · Entity 7735 | Director | April 13, 2026 | April 15, 2026 |
| RRE Ventures Acquisition Corp.RREV · Entity 5843 | Director | March 02, 2026 | May 05, 2026 |
| TAO Synergies Inc.TAOX · Entity 7482 | Director | May 18, 2026 | May 19, 2026 |
| WRAP TECHNOLOGIES, INC.WRAP · Entity 6770 | Director | October 01, 2026 | October 10, 2026 |
| XWELL, Inc.XWEL · Entity 1233 | Director | August 25, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neurotrope, Inc.
Report date December 01, 2020 · Filed December 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 1
1 source rowRow 1 · 2020-12-01 · Disposition to issuer · Disposed 1,565 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.32 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-12-01 · Disposition to issuer · Disposed 7,813 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.56 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-01 · Disposition to issuer · Disposed 15,535 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.10 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.91 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-12-01 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.06 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-12-01 · Disposition to issuer · Disposed 72,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held.
F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Petros Pharmaceuticals, Inc.
Report date June 05, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,762,334 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 1,875,000 · Balance 3,762,334 F1: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.
Q/C TECHNOLOGIES, INC.
Report date April 13, 2026 · Filed April 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2036-04-13 | Direct | 50,000 |
Reported balance
After 2026-04-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-13 · Grant · Acquired 50,000 · Balance 50,000 F1: The stock options are subject to expiration if the Reporting Person ceases to be employed by or provide services to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options are subject to expiration if the Reporting Person ceases to be employed by or provide services to the Issuer.
RRE Ventures Acquisition Corp.
Report date March 02, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 40,000 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 40,000 · Balance 40,000 F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date. F2: These securities were previously reported on a Form 3 filed by the Reporting Person. |
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 115,000 |
Reported balance
After 2026-03-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-25 · Grant · Acquired 75,000 · Balance 115,000 F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date. F2: These securities were previously reported on a Form 3 filed by the Reporting Person. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 | Direct | 250,000 |
Reported balance
After 2026-05-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-01 · Grant · Acquired 250,000 · Balance 250,000 F3: The private placement warrants will become exercisable 30 days after the completion of the Issuer's initial business combination and will expire five years after the completion of the Issuer's initial business combination or earlier upon liquidation. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date.
F2: These securities were previously reported on a Form 3 filed by the Reporting Person.
F3: The private placement warrants will become exercisable 30 days after the completion of the Issuer's initial business combination and will expire five years after the completion of the Issuer's initial business combination or earlier upon liquidation.
TAO Synergies Inc.
Report date May 18, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 · Expires 2036-05-18 | Direct | 55,000 |
Reported balance
After 2026-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-18 · Grant · Acquired 55,000 · Balance 55,000 F1: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following May 18, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following May 18, 2026.
WRAP TECHNOLOGIES, INC.
Report date October 01, 2026 · Filed October 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 272,002 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 21,154 · Balance 272,002 F1: Represents a grant of Restricted Stock Units ("RSUs"). On the date of grant, 13,750 of the RSUs vested and the remainder of the RSUs vest ratably in eight monthly tranches. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of Restricted Stock Units ("RSUs"). On the date of grant, 13,750 of the RSUs vested and the remainder of the RSUs vest ratably in eight monthly tranches.
XWELL, Inc.
Report date August 25, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 839,882 |
Reported balance
After 2026-08-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-25 · Grant · Acquired 500,000 · Balance 839,882 F1: Represents restricted shares of the Issuer's common stock, par value $0.01 which vested fully on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted shares of the Issuer's common stock, par value $0.01 which vested fully on the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 10, 2026 01:30 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantCommon Stock | 21,154 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-046645 · ownership.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,002 F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). On the date of grant, 13,750 of the RSUs vested and the remainder of the RSUs vest ratably in eight monthly tranches. Read SEC document |
| August 25, 2026 Filed Sep 3, 2026 01:47 UTC | XWELL, Inc. XWEL · Entity 1233 | GrantCommon Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-104860 · tm2624717-2_4seq1.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 839,882 F1 · security: Represents restricted shares of the Issuer's common stock, par value $0.01 which vested fully on the date of grant. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:27 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantStock Option (Right to Buy) · Derivative | 34,998 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001493152-26-032223 · ownership.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,998 Underlying: Common Stock · 34,998 shares Expires 2036-07-01 Read SEC document |
| June 05, 2026 Filed Jun 5, 2026 21:12 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantCommon Stock | 1,875,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-071039 · tm2617013-2_4seq1.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,762,334 F1 · shares: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. F1 · price: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. Read SEC document |
| May 18, 2026 Filed May 19, 2026 22:45 UTC | TAO Synergies Inc. TAOX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001104659-26-063994 · tm2615135-4_4seq1.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock, par value $0.0001 per share · 55,000 shares Expires 2036-05-18 F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following May 18, 2026. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:30 UTC | RRE Ventures Acquisition Corp. RREV · Entity 5843 | GrantWarrant · Derivative | 250,000 | $1.00 Strike: $11.50 | $250,000.00 |
DisclosureSEC source: 0001193125-26-206541 · ownership.xml · derivative · entry 3 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Class A Ordinary Shares · 250,000 shares Expires not disclosed F3 · derivative.exercise_date: The private placement warrants will become exercisable 30 days after the completion of the Issuer's initial business combination and will expire five years after the completion of the Issuer's initial business combination or earlier upon liquidation. F3 · derivative.expiration_date: The private placement warrants will become exercisable 30 days after the completion of the Issuer's initial business combination and will expire five years after the completion of the Issuer's initial business combination or earlier upon liquidation. Read SEC document |
| April 13, 2026 Filed Apr 15, 2026 22:29 UTC | Q/C TECHNOLOGIES, INC. QCLS · Entity 7735 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001493152-26-016909 · ownership.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-04-13 F1 · derivative.expiration_date: The stock options are subject to expiration if the Reporting Person ceases to be employed by or provide services to the Issuer. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:01 UTC | TAO Synergies Inc. TAOX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 800 | $0.00 Strike: $5.52 | $0.00 |
DisclosureSEC source: 0001104659-26-040884 · tm2611352-1_4seq1.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800 Underlying: Common Stock, par value $0.0001 per share · 800 shares Expires 2036-04-07 F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following April 7, 2026. Read SEC document |
| April 01, 2026 Filed May 2, 2026 01:03 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantCommon Stock | 19,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-020973 · ownership.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,848 F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). On the date of grant, 12,768 of the RSUs vested and the remainder of the RSUs vest ratably in eight monthly tranches. Read SEC document |
| March 25, 2026 Filed May 5, 2026 20:30 UTC | RRE Ventures Acquisition Corp. RREV · Entity 5843 | GrantClass B Ordinary Shares · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-206541 · ownership.xml · derivative · entry 2 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,000 Underlying: Class A Ordinary Shares · 75,000 shares Expires not disclosed F1 · derivative.exercise_price: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date. F1 · derivative.exercise_date: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date. F1 · derivative.expiration_date: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date. F2 · balance_after: These securities were previously reported on a Form 3 filed by the Reporting Person. Read SEC document |
| March 02, 2026 Filed May 5, 2026 20:30 UTC | RRE Ventures Acquisition Corp. RREV · Entity 5843 | GrantClass B Ordinary Shares · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-206541 · ownership.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Class A Ordinary Shares · 40,000 shares Expires not disclosed F1 · derivative.exercise_price: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date. F1 · derivative.exercise_date: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date. F1 · derivative.expiration_date: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date. F2 · balance_after: These securities were previously reported on a Form 3 filed by the Reporting Person. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 00:42 UTC | XWELL, Inc. XWEL · Entity 1233 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-022413 · tm267701-2_4seq1.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 339,882 F1 · security: Represents 100,000 restricted stock units ("RSUs"), which such RSUs shall vest on the thirtieth (30th) day following the date of grant, provided that the reporting person remains employed by or is providing services to the Issuer. The RSUs were granted subject to the closing of the transaction contemplated by that certain securities purchase agreement, dated as of February 24, 2026, by and between the Company and the purchaser signatory thereto, which occurred on February 27, 2026. Read SEC document |
| February 01, 2026 Filed Feb 4, 2026 02:47 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001493152-26-004978 · ownership.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-02-01 F1 · derivative.exercise_date: 33,000 of the stock options vested on the date of grant and the remainder will vest ratably in three annual tranches thereafter, provided that the Reporting Person is employed or providing services to the Issuer on the applicable vesting date. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 02:21 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantCommon Stock | 10,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-001923 · ownership.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,205 F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). On the date of grant, 3,123 of the RSUs vested and the remainder of the RSUs vest ratably in eleven monthly tranches. Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 22:00 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantCommon Stock | 1,875,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-000233 · tm261718-1_4seq1.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,887,334 F1 · shares: Represents Restricted Stock Units ("RSUs"). 50% of the RSUs vested on the date of grant and the remaining 50% will vest on the six month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. Each RSU represents the right to receive one share of common stock, par value $0.0001 per share (the "Common Stock"), of the Issuer. F1 · price: Represents Restricted Stock Units ("RSUs"). 50% of the RSUs vested on the date of grant and the remaining 50% will vest on the six month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. Each RSU represents the right to receive one share of common stock, par value $0.0001 per share (the "Common Stock"), of the Issuer. F2 · balance_after: Amounts adjusted for the Issuer's 1-for-25 reverse stock split of the Issuer's Common Stock, effective as of 4:05 p.m. (New York time) on April 30, 2025. Read SEC document |
| January 01, 2026 Filed Jan 6, 2026 00:42 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantCommon Stock | 12,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-000466 · ownership.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,796 F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). On the date of grant, 8,262 of the RSUs vested and the remainder of the RSUs vest ratably in eight monthly tranches. Read SEC document |
| November 14, 2025 Filed Nov 15, 2025 01:15 UTC | Q/C TECHNOLOGIES, INC. QCLS · Entity 7735 | GrantCommon stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-023697 · ownership.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). The RSUs were granted to the Reporting Person on October 3, 2025, subject to stockholder approval of an amendment to the Issuer's Q/C Technologies, Inc. 2021 Equity Incentive Plan (the "Plan Amendment"), under which the RSUs were granted. The Issuer's stockholders approved the Plan Amendment on November 14, 2025. The RSUs vested immediately upon issuance. Read SEC document |
| October 17, 2025 Filed Oct 17, 2025 21:09 UTC | TAO Synergies Inc. TAOX · Entity 7482 | Tax withholdingCommon Stock, par value $0.0001 per share | 10,000 | $7.23 | $72,300.00 |
DisclosureSEC source: 0001104659-25-100457 · tm2529010-1_4seq1.xml · nonDerivative · entry 2 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,897 F2 · shares: Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction. Read SEC document |
| October 17, 2025 Filed Oct 17, 2025 21:09 UTC | TAO Synergies Inc. TAOX · Entity 7482 | GrantCommon Stock, par value $0.0001 per share | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-100457 · tm2529010-1_4seq1.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,897 F1 · balance_after: Includes (i) 25,000 restricted stock units granted on October 17, 2025, under TAO Synergies Inc.'s (the "Issuer") 2020 Equity Incentive Plan which vested immediately and (ii) 15,897 shares of common stock. Read SEC document |
| October 01, 2025 Filed Oct 8, 2025 21:30 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantCommon Stock | 13,940 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-017471 · ownership.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,086 F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). The RSUs were granted in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ended September 30, 2025. On the date of grant, 9,061 of the RSUs vested and the remainder of the RSUs vest ratably in eight monthly tranches. Read SEC document |
| August 06, 2025 Filed Oct 17, 2025 21:09 UTC | TAO Synergies Inc. TAOX · Entity 7482 | GrantEmployee Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001104659-25-100457 · tm2529010-1_4seq1.xml · derivative · entry 3 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2035-07-14 F3 · date: The option grant was approved by a committee of the Issuer's board of directors on July 14, 2025 subject to shareholder approval of an amendment to the Company's 2020 Equity Incentive Plan (the "Plan") to increase the number of shares authorized for issuance of awards under the Plan. The Company received shareholder approval of the amendment to the Plan on August 6, 2025. Read SEC document |
| July 01, 2025 Filed Jul 11, 2025 00:35 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantCommon Stock | 19,391 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-018651 · ownership.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,146 F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). The RSUs were granted in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ended June 30, 2025. On the date of grant, 12,604 of the RSUs vested and the remainder of the RSUs vest ratably in eight monthly tranches. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:05 UTC | TAO Synergies Inc. TAOX · Entity 7482 | Tax withholdingCommon Stock, par value $0.0001 per share | 9,863 | $7.85 | $77,424.55 |
DisclosureSEC source: 0001104659-25-065275 · tm2519649-2_4seq1.xml · nonDerivative · entry 2 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,897 F2 · shares: Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:05 UTC | TAO Synergies Inc. TAOX · Entity 7482 | GrantCommon Stock, par value $0.0001 per share | 24,657 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-065275 · tm2519649-2_4seq1.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,760 F1 · balance_after: Includes (i) 24,657 restricted stock units granted on June 30, 2025, under the Issuer's 2020 Equity Incentive Plan which vested immediately upon issuance and (ii) 1,103 shares of common stock. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 12:00 UTC | XWELL, Inc. XWEL · Entity 1233 | GrantEmployee stock option (right to buy) · Derivative | 220,528 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001104659-25-055727 · tm2517003-1_4seq1.xml · derivative · entry 2 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,528 Underlying: Common Stock · 220,528 shares Expires 2035-06-02 F2 · security: Represents stock options to purchase up to 220,528 shares of Common Stock with such stock options vesting in four substantially equal installments on the quarterly anniversaries of the grant date, provided that the reporting person is providing services to the Company through such vesting date. F2 · derivative.exercise_date: Represents stock options to purchase up to 220,528 shares of Common Stock with such stock options vesting in four substantially equal installments on the quarterly anniversaries of the grant date, provided that the reporting person is providing services to the Company through such vesting date. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 12:00 UTC | XWELL, Inc. XWEL · Entity 1233 | GrantCommon Stock, par value $0.01 | 200,926 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-055727 · tm2517003-1_4seq1.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,882 F1 · price: The reporting person received fully vested restricted stock units, in consideration of the reporting person's Board fees decrease effective in the fourth quarter of 2024. Read SEC document |
| April 10, 2025 Filed Apr 17, 2025 01:26 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantCommon Stock | 19,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-012195 · rdgdoc.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,755 F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). The RSUs were granted in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ended March 31, 2025. On the date of grant, 12,767 of the RSUs vested and the remainder of the RSUs vest ratably in eight monthly tranches. Read SEC document |
| April 03, 2025 Filed Apr 7, 2025 21:00 UTC | TAO Synergies Inc. SNPX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 800 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001104659-25-032679 · tm2511539-1_4seq1.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800 Underlying: Common Stock, par value $0.0001 per share · 800 shares Expires 2035-04-03 F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following April 3, 2025. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:30 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-016197 · tm257316-1_4seq1.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308,346 F1 · price: Represents a grant of restricted shares of common stock, par value $0.0001 per share, of the Issuer granted under the Petros Pharmaceuticals, Inc. Amended and Restated 2020 Omnibus Incentive Compensation Plan, as amended. 50% of the shares vest on the first anniversary of the date of grant and the remaining shares vest on the second anniversary on the date of grant, provided that the Reporting Person continues to provide service to the Issuer on the applicable vesting date. Read SEC document |
| February 05, 2025 Filed Feb 13, 2025 23:01 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantCommon Stock | 9,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-003791 · rdgdoc.xml · nonDerivative · entry 2 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,061 F2 · price: Represents a grant of RSUs. The RSUs were granted in connection with the Reporting Person's service as the chair of the Audit of the Board of Directors of the Issuer. 30% of the RSUs vested on the date of grant and the remaining 70% of the RSUs will vest in in equal monthly installments through the remainder of 2025, provided the Reporting Person is employed by or providing services to the Issuer on the applicable vesting date. Read SEC document |
| February 05, 2025 Filed Feb 13, 2025 23:01 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantCommon Stock | 5,051 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-003791 · rdgdoc.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,112 F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). The RSUs were granted in connection with the Reporting Person's service as the chair of the Compensation Committee of the Board of Directors of the Issuer. 30% of the RSUs vested on the date of grant and the remaining 70% of the RSUs will vest in in equal monthly installments through the remainder of 2025, provided the Reporting Person is employed by or providing services to the Issuer on the applicable vesting date. Read SEC document |
| January 01, 2025 Filed Jan 7, 2025 02:53 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantCommon Stock | 14,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-000544 · rdgdoc.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,970 F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). The RSUs were granted in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ended December 31, 2024. On the date of grant, 9,274 of the RSUs vested and the remainder of RSUs vest ratably in eight monthly tranches. Read SEC document |
| November 15, 2024 Filed Nov 18, 2024 23:33 UTC | XWELL, Inc. XWEL · Entity 1233 | GrantEmployee stock option (right to buy) · Derivative | 44,037 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001104659-24-120234 · tm2428798-1_4seq1.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,037 Underlying: Common Stock · 44,037 shares Expires 2034-11-15 F1 · security: Represents stock options to purchase up to 44,037 shares of Common Stock with such stock options vesting 100% on the first anniversary of the date of the grant, provided that the reporting person is providing services to the Company through such vesting date. F1 · derivative.exercise_date: Represents stock options to purchase up to 44,037 shares of Common Stock with such stock options vesting 100% on the first anniversary of the date of the grant, provided that the reporting person is providing services to the Company through such vesting date. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:10 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantCommon Stock | 20,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-030608 · rdgdoc.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,701 F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). The RSUs were granted in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ended September 30, 2024. On the date of grant, 13,109 of the RSUs vested and the remainder of RSUs vest ratably in eight monthly tranches. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 10:11 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantCommon Stock | 15,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-022073 · rdgdoc.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,534 F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). The RSUs were granted in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ended June 30, 2024. On the date of grant, 9,831 of the RSUs vested and the remainder of RSUs vest ratably in eight monthly tranches. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 20:05 UTC | TAO Synergies Inc. SNPX · Entity 7482 | GrantStock Option (Right to Buy) · Derivative | 800 | $0.00 Strike: $5.39 | $0.00 |
DisclosureSEC source: 0001104659-24-045797 · tm2411531-1_4seq1.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800 Underlying: Common Stock, par value $0.0001 per share · 800 shares Expires 2034-04-08 F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following April 8, 2024. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:25 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantCommon Stock | 13,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-010926 · rdgdoc.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,409 F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). The RSUs were granted in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ended March 31, 2024. On the date of grant, 30% of the RSUs vested and the remainder of RSUs vest ratably in eight monthly tranches beginning May 1, 2024. Read SEC document |
| January 14, 2024 Filed Jan 19, 2024 02:29 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantCommon Stock | 4,786 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-001669 · rdgdoc.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,810 F1 · price: The shares of common stock, par value $0.0001 per share, of the Issuer were granted in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ended December 31, 2023. Read SEC document |
| January 02, 2024 Filed Jan 19, 2024 02:12 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantCommon Stock | 9,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-001662 · rdgdoc.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,024 F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). The RSUs were granted in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ended December 31, 2023. On the date of grant, 30% of the RSUs vested and the remainder of RSUs vest ratably in eight monthly tranches beginning February 1, 2024. Read SEC document |
| December 22, 2023 Filed Jan 9, 2024 02:57 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0001437749-24-000914 · rdgdoc.xml · derivative · entry 2 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-12-22 F2 · derivative.exercise_date: The stock options vested 100% on the date of grant. Read SEC document |
| December 22, 2023 Filed Jan 9, 2024 02:57 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-000914 · rdgdoc.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,266 F1 · price: Represents a grant of Restricted Stock Units (the "RSUs"). The RUSs will vest in three substantially equal installments at the end of each of the Issuer's fiscal years beginning on December 31, 2024 and ending on December 31, 2026, provided the Reporting Person is employed by or providing services to the Company or an affiliate on the applicable vesting date. Read SEC document |
| December 22, 2023 Filed Jan 10, 2024 01:35 UTC Amendment | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0001437749-24-001036 · rdgdoc.xml · derivative · entry 2 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-12-22 F2 · derivative.exercise_date: The stock options vested 100% on the date of grant. Read SEC document |
| December 22, 2023 Filed Jan 10, 2024 01:35 UTC Amendment | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-001036 · rdgdoc.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,266 F1 · price: Represents a grant of Restricted Stock Units (the "RSUs"). The RUSs will vest in three substantially equal installments at the end of each of the Issuer's fiscal years beginning on December 31, 2024 and ending on December 31, 2026, provided the Reporting Person is employed by or providing services to the Company or an affiliate on the applicable vesting date. Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 22:08 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001104659-23-129255 · tm2333705-3_4seq1.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-12-21 F1 · derivative.exercise_date: The stock options will vest on April 10, 2024, provided that the Reporting Person has continued to provide services to Petros Pharmaceuticals, Inc. through the vesting date. Read SEC document |
| September 30, 2023 Filed Oct 19, 2023 20:11 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantCommon Stock | 10,083 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-014431 · form4-10192023_081010.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,266 F1 · price: Represents shares of Restricted Stock (the "Shares") issued in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ended September 30, 2023. The number of Shares was calculated based on the amount due the Reporting Person at the end of the quarter, or $15,125, divided by the closing price of the Company's Common Stock on such date. 30% of the Shares were vested as of the date of the grant, with the remainder vesting ratably in eight monthly tranches beginning November 1, 2023. Read SEC document |
| July 07, 2023 Filed Jul 10, 2023 17:50 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantCommon Stock | 8,083 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-010979 · form4-07102023_050750.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,183 F1 · price: Represents shares of Restricted Stock (the "Shares") issued in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ended June 30, 2023. The number of Shares was calculated based on the amount due the Reporting Person at the end of the quarter, or $11,800, divided by the closing price of the Company's Common Stock on such date. 30% of the Shares were vested as of the date of the grant, with the remainder vesting ratably in eight monthly tranches beginning August 1, 2023. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 22:02 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | Exercise / conversionRestricted Stock Units · Derivative | 6,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-053226 · tm2313909-3_4seq1.xml · derivative · entry 2 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,050 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer. F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. F2 · derivative.exercise_date: On April 7, 2022, the reporting person was granted 6,050 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023. F2 · derivative.expiration_date: On April 7, 2022, the reporting person was granted 6,050 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023. F1 · derivative.underlying_shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 22:02 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | Exercise / conversionCommon Stock | 6,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-053226 · tm2313909-3_4seq1.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. F2 · price: On April 7, 2022, the reporting person was granted 6,050 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023. F1 · balance_after: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. Read SEC document |
| April 21, 2023 Filed Apr 27, 2023 00:24 UTC | WRAP TECHNOLOGIES, INC. WRAP · Entity 6770 | GrantStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $1.34 | Not disclosed |
DisclosureSEC source: 0001415889-23-006942 · form4-04272023_120431.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-04-21 F2 · price: Grant awarded in connection with the Reporting Person's appointment as a member of the Board of Directors of the Issuer. F1 · derivative.exercise_date: 50% of the stock options shall vest on the one-year anniversary of the grant date, with the remainder vesting in four equal quarterly installments thereafter. Read SEC document |
| April 10, 2023 Filed Apr 12, 2023 22:00 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantStock Option (Right to Buy) · Derivative | 39,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001104659-23-044709 · tm2312600-1_4seq1.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,000 Underlying: Common Stock · 39,000 shares Expires 2033-04-10 F1 · derivative.exercise_date: The stock options will vest on the one-year anniversary of the date of grant, provided that the Reporting Person has continued to provide services to Petros Pharmaceuticals, Inc. (the "Company") through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.